BIAL Announces First Patient Out in its Phase 2 Clinical Trial of BIA 28-6156 – a Novel Therapy for GBA1 Parkinson’s Disease

PORTO, Portugal, Jan. 7, 2025 /PRNewswire/ — BIAL, a hundred-year-old innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced that the first patient has completed the full dose regimen in the ACTIVATE Phase 2 study. BIA 28-6156 is a…